BERLIN (AP) — Adam Pemble, an Associated Press video journalist who covered some of the biggest global news of the past two decades, from earthquakes and conflicts to political summits and elections, has died. He was 52. Pemble died Thursday in Minneapolis surrounded by friends and family, according to his friend Mike Moe, who helped care for him in the final weeks of his fight against cancer. Known for bringing stories alive with his camera, Pemble epitomized the best of television news traditions, casting a curious and compassionate lens onto the lives of the people and communities whose stories he told. He joined the AP in 2007 in New York before moving to Prague in 2011 to help launch AP’s first cross-format operation combining photography, text stories and video. He enhanced Eastern European news coverage, creating distinctive stories highlighting the region's culture and society. “Adam was an incredibly talented and passionate journalist and an empathetic storyteller. He had this amazing ability to get anyone to talk to him on camera, which I attribute to the Midwestern charm he embodied throughout his life." said Sara Gillesby, AP’s Director of Global Video and Pemble’s former manager in New York when he joined the AP. "He was the best of us.” Pemble was born in Saint Louis Park, Minnesota, in 1972 and grew up in Minneapolis. After graduating with a degree in mass communications from Minnesota State University Moorhead, he started his journalism career in 1997 at KVLY, a television station in Fargo, North Dakota, and later worked at WCCO in Minneapolis. “He had the skills of the old-school camera people to meet a deadline and turn a beautiful story,” said Arthur Phillips, a cameraman who worked with Pemble at WCCO. “But he had a calling for greater things.” Moving to New York, Pemble covered some of the biggest stories in the city, including the trial of Bernie Madoff, interviews with former Iranian President Mahmoud Ahmadinejad and with then-real estate developer, now U.S. president-elect, Donald Trump. He went to Haiti to cover the aftermath of the 2010 earthquake, where he captured shocking images of devastation. A few weeks later he was in Vancouver, covering the Winter Olympics. With his transfer to Prague, Pemble quickly became the go-to video journalist deployed to the biggest news events in Europe, interviewing government leaders, covering violent protests, the aftermath of terror attacks and numerous national elections across the continent. “An inquiring mind, a keen eye and a healthy skepticism for those in power who tried to spin away from truth all combined to make Adam’s stories as rich in color as he was in character," said Sandy MacIntyre, former AP head of global video. "Time and again he was asked to do the impossible and without fail he delivered the exceptional.” ”But more than all of that, he was the colleague and friend you wanted by your side because if Adam was there we knew we were going to be the winning team.” As civil unrest rocked Ukraine in 2014, Pemble reported from Kyiv and later Donetsk, where he covered the first Russian-backed demonstrations before spending weeks in Crimea during Russia's annexation of the strategic peninsula. His video reports included the last remaining Ukrainian sailors loyal to Kyiv finally abandoning their ship and coming ashore. With the Russian national anthem playing from a car in the background, his final shot showed two distraught sailors heckled as they walked away. Pemble returned to Ukraine following Russia's invasion of the country in 2022. Among his many assignments was filming the exclusive March 2023 AP interview by Executive Editor Julie Pace with Ukrainian President Volodymyr Zelenskyy as a train shuttled them across Ukraine to cities near some of the fiercest fighting. “Adam showed up to every assignment with enthusiasm, creativity and commitment to his work and his colleagues. He loved what he did, and so many of us at AP are better for having worked alongside him,” Pace said. When not deployed overseas, Pemble set his camera's gaze on his new home in the Czech Republic, offering insight into the traditions and unique stories of Eastern Europe. From Christmas carp fishing at sunrise to graffiti artists in Prague, to the intimate story of a Slovak priest challenging the celibacy rules of the Catholic Church, he brought his unmistakable style. He worked with a traditional large broadcast camera in an era where many video shooters shifted to smaller, lighter cameras. He always put himself in the right place to let reality unfold like “an old school analog painter in an often fast and furious digital age,” former AP cameraman Ben Jary recalled. Pemble's interest in visual storytelling led to experimenting with new technologies, including aerial videography. In 2015, he was the first major news agency camera operator to film live drone footage when reporting on the migration crisis in the Balkans. An avid gardener who planted trees and chilis on his rooftop in Prague, he was adventurous in the kitchen and especially proud of his vegan “meatloaf,” friends said. He loved a seedy dive bar as much as a Michelin restaurant, and foods as varied as charcoal choux pastry with truffle creme and his favorite road trip junk food, Slim Jim’s jerky and Salted Nut Rolls. Pemble’s wit, wisdom, energy and positivity enriched the lives and experiences of those around him, friends and colleagues recalled. “If someone asked me to see a picture of quiet strength and courage, dignity and grace, and most of all kindness, I would show them a picture of a man for all seasons," said Dan Huff, a Washington-based AP video journalist, "I would show them a picture of Adam Pemble."
Ocular Hypertension Pipeline Forecast 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Developments | Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Resea 11-22-2024 09:27 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ocular Hypertension pipeline constitutes 70+ key companies continuously working towards developing 75+ Ocular Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Ocular Hypertension Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ocular Hypertension Market. The Ocular Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Ocular Hypertension Pipeline Report: https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Ocular Hypertension treatment therapies with a considerable amount of success over the years. •Ocular Hypertension companies working in the treatment market are Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others, are developing therapies for the Ocular Hypertension treatment •Emerging Ocular Hypertension therapies in the different phases of clinical trials are- LUMIGAN®, TO-O-1001, AR-17043, OPC-1085EL, QLS-111, NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others are expected to have a significant impact on the Ocular Hypertension market in the coming years. •In November 2024, MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company based in San Diego, has announced the results of its Phase 2b clinical trial for LL-BMT1. Utilizing an innovative 3D-printed, drug-eluting contact lens designed for sustained delivery of bimatoprost and hyaluronic acid, the trial successfully met all Phase 2b endpoints. Presented by Dr. Ian Ben Gaddie at the American Academy of Optometry's annual meeting in Indianapolis, the findings highlighted LL-BMT1's potential as a groundbreaking solution for managing mild to moderate glaucoma while enhancing contact lens comfort by alleviating dry eye symptoms. •In April 2024, Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company dedicated to improving vision and quality of life through innovative treatments for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other eye disorders, has announced positive Phase 2 results for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension. Ocular Hypertension Overview Ocular hypertension refers to elevated intraocular pressure (IOP) within the eye that exceeds the normal range, typically above 21 mmHg, without causing detectable damage to the optic nerve or vision loss. It is a significant risk factor for developing glaucoma, particularly open-angle glaucoma. Ocular hypertension occurs when the eye's aqueous humor drainage is impaired, leading to increased fluid buildup and pressure. Common risk factors include age, family history, thin corneas, and certain medications. Early detection and management are crucial to prevent progression to glaucoma, often involving regular monitoring and medications to lower IOP. Get a Free Sample PDF Report to know more about Ocular Hypertension Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Ocular Hypertension Drugs Under Different Phases of Clinical Development Include: •T4090: Laboratoires Thea •Xalatan: Rigshospitalet •Reference - LUMIGAN®: Amneal Pharmaceuticals •TO-O-1001: Theratocular Biotek Co. •AR-17043: Alcon Research •OPC-1085EL: Otsuka Beijing Research Institute •QLS-111: Qlaris Bio, Inc. •NCX 470: Nicox Ophthalmics •Nyxol: Ocuphire Pharma •Sepetaprost(DE-126/ONO-9054/STN1012600 ): Santen Inc. /Ono Pharmaceutical •LL-BMT1: MediPrint Ophthalmics •PDP-716: Visiox Pharma/ Sun Pharma Advanced Research Company •JV-GL1: JeniVision, Inc. •NCX 470: Nicox Ophthalmics, Inc. •Kinezodianone R hydrochloride: Laboratoires Thea •G2-TR intraocular implant containing travoprost: Glaukos Corporation •H-1337: D. Western Therapeutics Institute, Inc. •AGN-193408 SR: AbbVie •Latanoprost ophthalmic solution: TearClear Corp •OTX-TIC: Ocular Therapeutix, Inc. •PER-001: Perfuse Therapeutics, Inc. Ocular Hypertension Route of Administration Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Ocular Hypertension Molecule Type Ocular Hypertension Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Ocular Hypertension Pipeline Therapeutics Assessment •Ocular Hypertension Assessment by Product Type •Ocular Hypertension By Stage and Product Type •Ocular Hypertension Assessment by Route of Administration •Ocular Hypertension By Stage and Route of Administration •Ocular Hypertension Assessment by Molecule Type •Ocular Hypertension by Stage and Molecule Type DelveInsight's Ocular Hypertension Report covers around 75+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Ocular Hypertension product details are provided in the report. Download the Ocular Hypertension pipeline report to learn more about the emerging Ocular Hypertension therapies at: https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Ocular Hypertension Therapeutics Market include: Key companies developing therapies for Ocular Hypertension are - JeniVision, Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others. Ocular Hypertension Pipeline Analysis: The Ocular Hypertension pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Ocular Hypertension with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ocular Hypertension Treatment. •Ocular Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Ocular Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ocular Hypertension market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Ocular Hypertension drugs and therapies- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Ocular Hypertension Pipeline Market Drivers •Growing Prevalence, Advancements in Research, Rising Awareness, Regulatory Support, Investment in R&D, are some of the important factors that are fueling the Ocular Hypertension Market. Ocular Hypertension Pipeline Market Barriers •However, High Development Costs, Regulatory Challenges, Limited Patient Compliance, Competitive Landscape, Healthcare Access Disparities, and other factors are creating obstacles in the Ocular Hypertension Market growth. Scope of Ocular Hypertension Pipeline Drug Insight •Coverage: Global •Key Ocular Hypertension Companies: Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others •Key Ocular Hypertension Therapies: LUMIGAN®, TO-O-1001, AR-17043, OPC-1085EL, QLS-111, NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others •Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies •Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers Request for Sample PDF Report for Ocular Hypertension Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Ocular Hypertension Report Introduction 2. Ocular Hypertension Executive Summary 3. Ocular Hypertension Overview 4. Ocular Hypertension- Analytical Perspective In-depth Commercial Assessment 5. Ocular Hypertension Pipeline Therapeutics 6. Ocular Hypertension Late Stage Products (Phase II/III) 7. Ocular Hypertension Mid Stage Products (Phase II) 8. Ocular Hypertension Early Stage Products (Phase I) 9. Ocular Hypertension Preclinical Stage Products 10. Ocular Hypertension Therapeutics Assessment 11. Ocular Hypertension Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Ocular Hypertension Key Companies 14. Ocular Hypertension Key Products 15. Ocular Hypertension Unmet Needs 16 . Ocular Hypertension Market Drivers and Barriers 17. Ocular Hypertension Future Perspectives and Conclusion 18. Ocular Hypertension Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Ocular Hypertension Market https://www.delveinsight.com/report-store/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Ocular Hypertension Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Ocular Hypertension Epidemiology https://www.delveinsight.com/report-store/ocular-hypertension-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Ocular Hypertension Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports: •Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market •Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market •Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market •Neuroendoscopy Market: https://www.delveinsight.com/report-store/neuroendoscopy-market •Nosocomial Infections Market: https://www.delveinsight.com/report-store/nosocomial-infections-market •Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.Philadelphia takes on Vegas after overtime winWith summer upon us, cranking up the air conditioning is the most comfortable option, but the electricity bill that goes with it can be shocking. That’s why Australians who have a house, a roof and some money are increasingly getting solar panels. But there is a problem because there is a thing as too much solar. Today, energy reporter Dan Mercer explains that the surge of solar power is risking stability of the power grid and it’s a bit like riding a bike. Featured: Dan Mercer, ABC energy reporter on the . With summer upon us, cranking up the air conditioning is the most comfortable option. But the electricity bill that goes with it can be, well, rude. That's probably why more Australians than ever now have solar panels. But while that sounds pretty good, there is a problem. Because, yes, there is a thing as too much solar. Today, energy reporter Dan Mercer explains why. I'm Sam Hawley on Gadigal land in Sydney. This is ABC News Daily. Dan, it's getting really hot now, of course, because summer is here and we know in Australia there is going to be a heap of sunshine, which is really good news if you have solar panels on your roof. And, oh, my, there are so many people that actually have that now, aren't there? Yeah, it's a remarkable number of people, Sam. By the federal government's estimates, a couple of weeks ago we had our four millionth rooftop solar installation, which is a big number in a country like Australia. And certainly a bunch of them are on small businesses and commercial buildings. But, you know, any way you dice it, there's just no doubt that Australia has an extraordinary amount of solar on rooftops. And when you think that just 20 years ago there were barely any panels anywhere, it's incredible. That's brilliant, isn't it? And it's really providing relief for people on their bills because, of course, if you don't have it, the electricity bill, the power bills, you know, they can come as a pretty big shock most of the time. Yeah, I think in the main that's right. The rule of thumb is that solar will cut your bills these days by about 30 odd per cent. There's probably still a perception, I reckon, in some circles that you can somehow win by selling the surplus solar back to the grid. But the reality is there's now so much solar being generated in the middle of the day across Australia that the output is valued at close to zero by the market. You know, so using the power yourself is really the ticket and it sure beats buying the electricity from the grid. I spoke to one Sydney householder, Kerry Bradbury. I live in Chifley, New South Wales, and I work for the New South Wales Health. She was getting stung by very high bills until recently, like many Australians have been. And it got to the stage where you're actually afraid to open your electricity bill because in those days it came in the mail. She's got three kids. I think they're all adults. And they don't strictly live at home with her, but they are occasional tenants. And also having three transient children, for want of a better word, coming in and out. I've had huge bills when they're here and not-so-huge bills when they're not here, when it's just me. And when they are there, or, you know, certainly until recently, when they were there, she said she was getting bills of up to $2,000 a quarter. So she decided to take matters into her own hands. So she's basically what set herself up to use solar as much as she possibly can. So just tell me what she's got. She shelled out for a system that could basically take care of all her power needs. She installed batteries. She got new solar panels. She bought smart appliances and invested in some tech that could coordinate all of this for her. It's a smaller power provider that runs it all for her. And it wasn't cheap. It cost her about $28,000. Not the sort of money that the average person necessarily would have lying around. But she says she now won't have to pay a power bill for the next seven years. It is quite expensive, but you have to weigh up the cost, A, to the environment, if you can afford it, and how big your actual bills are. If you're getting hammered every time, you've got to look at other solutions. Yeah, that sounds pretty good. But then what happens after the seven years? Because $28,000, as you say, that's a pretty big number. I mean, to a large extent, it'll depend on her circumstances after seven years. But she might not have to pay any bills for a few more years after that. She might, on the other hand, have to replace the batteries because batteries do degrade. That's just a reality with them. But even then, batteries are likely to be much cheaper by then, Sam. That's certainly the forecast. All right. Well, Dan, Kerry, of course, was sick of her massive power bill. So she's done what lots of Australians have done and has tried to take advantage of the sun. And of course, we expect that number to keep growing. But things can get tricky because there is such a thing as too much solar. Yeah. I mean, it becomes a problem when solar supply eclipses demand for power from the grid. And you've got no way of using that excess generation or storing it somewhere. And realistically, we are reaching that point in Australia. At times. It's made worse or it's really kind of characterised by a technical phenomenon known as minimum demand. Now, energy nerds, and that's not the vast majority of Australians. That's you though, Dan, right? Well, you know, perhaps that's an uncharitable interpretation. It's a compliment. It's a compliment. But yeah, I mean, they have been talking and warning about this phenomenon for years. But it basically refers to demand for electricity from the grid. Yeah, that's key. And, you know, therefore it excludes demand for power that is being met behind the meter. So not on the grid. And that's basically a reference to rooftop solar. And, you know, as we've been discussing, the amount of rooftop solar in the system is now at such monumental levels. It's pushing that minimum demand to lower and lower and lower levels. The problem is we still need the grid. We need it to be there when the sun stops shining. And right now the grid is being propped up still by coal and gas-fired power plants to a very significant extent. But of course, solar is increasingly squeezing the sorts of conventional power plants out of the system. And so more and more of them are closing. Yeah, OK, but just explain that a bit further, because that actually sounds like a good thing, because aren't we meant to be reducing our reliance on coal and gas? Yes, but what we're basically seeing at the moment is a mismatch between the system we're trying to build and the one we've already got, the one that we're using right now. I mean, this energy transition is basically a story about rebuilding the entire electricity system from one that runs on fossil fuels to one that runs on renewable energy. And right now the old system is just struggling to cope with those vast amounts of solar power that are flooding onto the grid daily. Now, that's generally true. There is that much solar washing through the grid every day, even through winter a lot of the time, that it's almost invariably depressing wholesale prices in the middle of the day. But it's especially true in certain conditions. Think spring or autumn days when there's plenty of sunshine and output from solar is peaking, but demand for power is fairly subdued because the temperature is mild and people aren't using their air conditioners, which suck up an enormous amount of juice. In these circumstances, the demand for power from the grid, that is, demand for power that is not being met by rooftop solar, it's falling to extraordinarily low levels. OK, so then what happens when that happens? Why does that matter? it's a question of physics, basically. Now, I was no exemplary physics student at school. I bet you were. No, no, I most definitely wasn't. I don't believe you. But, you know, the people who run the system, you know, they understand these things thoroughly. And, you know, running a power system isn't just about generating electricity to meet demand. That's obviously,that's its most obvious purpose. It's also, though, about ensuring that, you know, that electricity is provided at a consistent frequency and at a safe voltage so our appliances work properly and don't get cooked. The system needs this really steady heartbeat to keep everything on an even keel. To do this, the system relies on things like inertia, which is basically the physical property that makes balancing a moving bike much, much easier than balancing a stationary one. And the simple reason for that is, you know, like the moving bicycle, these coal and gas and hydro plants are big pieces of spinning metal. They take a long time to get up and running and they take a long time to slow down once they've got a head of steam. But this helps keep the grid stable. You know, it helps it ride through shocks. And it's always been provided by these conventional power plants basically as a byproduct. So coal and gas power stations provide stability, but renewables don't. Yeah.The reality is that clean energy sources, wind, batteries, but particularly solar, they just don't intrinsically provide those services. They're connected to the grid by these bits of kit known as inverters that basically try to convert the electricity from the solar panels, for example, into a type that can be used in the grid. And they try to follow what's happening on the grid. And because the system, the grid, that is, is almost invariably up and running and ticking along nicely. These solar panels through the inverters can just plug in and follow along. But for the most part, they don't and they can't provide those sorts of system security services. They can't help maintain that heartbeat of the grid. I spoke with Alex Wonhas, who is a former executive at the Australian Energy Market Operator, AEMO. It basically becomes unstable and you have to either increase the load during that time to make it more stable or you have to basically reduce the solar output. So, Dan, let's look then at how we address this, because we want to use as much renewable energy as we can, right? We want to use as much sun as we can. That's right, Sam. Well, we're really only getting into the teeth of the transition now. Alex Wonhas says we're on the cusp of much better integrating all of this intermittent renewable energy. For starters, he says that inverter technology is actually getting much more sophisticated. By some accounts, there are now inverters that can provide a type of synthetic system security. And there's a view that these kinds of inverters will soon just become the norm. And so a lot of these problems might start to fall away. But then, of course, there's just something as simple as batteries. Alex Wonhasreckons batteries will be able to take care of a lot of these problems for us, because they'll be able to store so much of that excess solar power for use later in the day. Batteries can also go even further. They can, with the latest technology, they can actually provide inertia so that it can basically pretend to be a coal or a gas plant and provide that inertia. And they can also provide something which the technical people call system strength. So that's really the ability to keep the electricity waveform really nice and smooth, which is also something that you want in an electricity system. But importantly, there are other solutions that are out there. One of the biggest ones involves us as consumers, actually, Sam. We just have to change the way we use power. Historically, the supply of power has been there to meet demand. But increasingly, there's a view that demand should be much better at meeting supply. In other words, we should use as much of that renewable energy as we can while it's being generated. And for that, you can really read in the middle of the day when solar output is highest. Now, this doesn't mean we shouldn't use power outside of those times, of course. We can build storage to stash as much of that as possible away for later in the day. But storage costs money. You know, we don't try to capture every drop of water that falls out of the sky in dams. It would be cost prohibitive. And the same sort of thinking applies to solar power. So finding clever and equitable ways of shifting demand seems to be the key. All right. And that, of course, brings us back to Kerry, because she's someone who is really doing this well, isn't she? I'm sure she feels that way. And, you know, when I spoke to her, she certainly did feel that way. But, you know, she's got in her house smart tech that can do a lot of this heavy lifting for her. For example, she's got software that can automatically turn off or on appliances or can cycle them up and down, depending on the circumstances, how sunny it is, what time of the day it is, for example. More broadly, it could be as simple as a householder soaking up as much of their solar as they can during the middle of the day, pre-cooling their home in summer, pre-warming it in winter. The promise of this solution in particular, you know, changing how we use energy is really enormous, but it's only if we can get it right. The jury is out at the moment, Sam, on whether we can do that. It's a bit of an open question. Dan Mercer is the ABC's energy reporter based in WA. This episode was produced by Sydney Pead, Kara Jensen-MacKinnon and Anna John. Audio production by Sam Dunn. Our supervising producer is David Coady. I'm Sam Hawley. Thanks for listening.
IRVING, Texas (AP) — The NFL will consider expanding replay assist to include facemask penalties and other plays. Officials have missed several obvious facemask penalties this season, including two in a three-week span during Thursday night games. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.None
In promising to shake up Washington, Trump is in a class of his own
Matt Gaetz says he won’t return to Congress next year after withdrawing name for attorney general
None